Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination (original) (raw)

Abstract

In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n=143) and 0, 1, 2, 12 months (group 2; n=141) was performed in months 3, 7 and 12. In addition, the antibody response was compared one month after the third and one and six months after the last vaccination. Seroprotection rates (anti-HBS>10 IU/l) and antibody titres, given as geometric means (GMTs), were higher in group 1 at month 12 as well as one month after completion of three immunizations. More vaccinees of group 2, however, showed seroprotection at month 3 with higher GMTs. In addition, GMTs in group 2 were higher both one month and six months after the last vaccine dose. Determination of parallel corrected correlation factors demonstrated that age was the most important single factor, followed by body weight and sex. However, no more than 3 % of the variation in the GMT can be explained by the influence of age. Due to decreased compliance with the four-dose schedule with a drop-out rate of approximately 10 % of the vaccinees, the total percentage of initial vaccinees who in the end developed protective antibody levels was higher in the 0, 1, 6 months schedule. Thus, it can be concluded that subjects likely to comply will benefit from the 0, 1, 2, 12 months schedule as more rapid protection is obtained and the higher antibody levels after the booster vaccination at month 12 provide longer protection. However, vaccinees whose compliance might be questionable over a period of 12 months, should be selected for the vaccination 0, 1, 6 months schedule as compliance is at a higher level over this period and advantage can be taken of the booster effect of the third dose given in month 6.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Deinhardt F: Immunization against hepatitis B. Lancet 1988, i: 875–876.
    Google Scholar
  2. Jilg W, Deinhardt F: Hepatitis-B-Impfung heute. Münchner Medizinische Wochenschrift 1988, 130: 361–362.
    Google Scholar
  3. Jilg W, Schmidt M, Deinhardt F: Impfversagen nach Hepatitis-B-Impfung. Deutsche Medizinische Wochenschrift 1990, 115: 1545–1548.
    Google Scholar
  4. Filion LG, Saginur R, Szczerbak N: Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination. Clinics of Experimental Immunology 1988, 71: 405–409.
    Google Scholar
  5. Courouce-Pauty AM, Naret C, Ciancionnoni C, Adhemar JP, Soulier JP: Prevention of viral hepatitis B in haemodialysis units by means of anti-HBs immunoglobulins. In: Fondation Merieux: Transplantation and clinical immunology. Volume IX. Excerpta Medica, Amsterdam, 1978, p. 77.
    Google Scholar
  6. Dennhöfer L: Hepatitis-B Schutzimpfung. Zum Problem der ungenügenden anti-HBs-Bildung. Deutsche Medizinische Wochenschrift 1990, 115: 1560–1565.
    Google Scholar
  7. Hollinger FB: Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. American Journal of Medicine 1989, 87, Supplement 3A: 36–40.
    Google Scholar
  8. Hollinger FB, Adam E, Heilberg D, Melnick JL: Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE (ed): Viral hepatitis. Franklin Institute Press, Philadelphia, 1982, p. 451–466.
    Google Scholar
  9. Stephenne J: Recombinant versus plasma-derived hepatitis-B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine 1988, 6: 299–303.
    Google Scholar
  10. Zajac BA, West DJ, McAleer WJ, Scolnick EM: Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. Journal of Infection 1986, 13, Supplement A: 39–45.
    Google Scholar
  11. Andre FE: Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. American Journal of Medicine 1989, 87, Supplement 3A: 14–20.
    Google Scholar
  12. Andre FE: Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990, 8, Supplement: 574–578.
    Google Scholar
  13. Troisi CL, Hollinger FB: Hepatitis B vaccines. In: Popper H, Schaffner F (ed): Progress in liver diseases. Volume 9. Saunders, Orlando, 1989.
    Google Scholar
  14. Jilg W, Schmidt M, Deinhardt F: Four-year experience with a recombinant hepatitis B vaccine. Infection 1989, 17: 70–76.
    Google Scholar
  15. Krämer A, Sommer D, Hahn EG, Riecken O: German experimental hepatitis B vaccine. Influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers. Klinische Wochenschrift 1986, 64: 688–694.
    Google Scholar
  16. Shaw FE, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, Roehm RR, Talley WS, Hadler SC: The effect of anatomic injection site, age, and smoking on the immune response to hepatitis B vaccination. Vaccine 1989, 7: 425–430.
    Google Scholar
  17. Horowitz MM, Ershler WB, McKinney WP, Battiola RJ: Duration of immunity after hepatitis B vaccination. Efficacy of low-dose booster vaccine. Annals of Internal Medicine, 1988, 108: 185–189.
    Google Scholar
  18. Corrao G, Calleri M, Zotti M, Barral C, Russo R, Garella D, Ruggenini AM: Immune response to anti-HBV vaccination. Study of conditioning factors. European Journal of Epidemiology 1988, 4: 492–496.
    Google Scholar
  19. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon MS: Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. Journal of the American Medical Association 1985, 254: 3187–3189.
    Google Scholar
  20. Kammler E, Klingler W: Hepatitis-B-Schutzimpfung. Münchner Medizinische Wochenschrift 1989, 131: 337–340.
    Google Scholar
  21. Novicki MJ, Tong MJ, Bohmann RE: Alterations in the immune response of nonresponders to the hepatitis B vaccine. Journal of Infectious Diseases 1985, 152: 1245–1248.
    Google Scholar
  22. Hess G, Rossol S, Voth R, Cheatham-Speth, Clemens R, Meyer zum Büschenfelde KH: Active immunization of homosexual men using a recombinant hepatitis B vaccine. Journal of Medical Virology 1989, 29: 229–231.
    Google Scholar
  23. Carne CA, Weller IVD, Waite J, Briggs M, Pearce F, Adler MW, Tedder RS: Impaired responsiveness of homosexual men with HIV-antibodies to plasma derived hepatitis B vaccine. British Medical Journal 1987, 294: 866–868.
    Google Scholar
  24. Köhler H, Dumann H, Meuer S: Hepatitis-B-Impfung bei Dialysepatienten. Deutsche Medizinische Wochenschrift 1990, 115: 264–269.
    Google Scholar
  25. Bruguera M, Cremades M, Rodicio JL, Alcantar JM, Oliver A, Del Rio G, Esteban-Mur R: Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. American Journal of Medicine 1989, 87, Supplement 3A: 30–32.
    Google Scholar
  26. Krämer A, Herth D, von Keyserlingk, Ludwig WD, Hampl H, Sommer D, Hahn EG, Riecken E: Non-responsiveness to hepatitis B vaccination: revaccination and immunogenetic typing. Klinische Wochenschrift 1988, 66: 670–674.
    Google Scholar
  27. Chriske HW, Bock HL, Clemens R: Immunantwort auf Nachimpfungen mit einer rekombinierten Hepatitis B-Vakzine bei Low-and Non-Respondern. Arbeitsmedizin Sozialmedizin Präventivmedizin 1990, 25: 421–422.
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Medical Department, University Hospital of Mainz, Langenbeckstr. 1, 6500, Mainz, Germany
    G. Hess
  2. Department of Hygiene, University of Heidelberg, Im Neuenheimer Feld 324, 6900, Heidelberg, Germany
    V. Hingst
  3. University Hospital of Gießen, Friedrichstr. 16, 6300, Gießen, Germany
    J. Cseke
  4. Medical Department, Smith Kline Beecham Pharma, Sapporobogen 6–8, 8000, Munich, Germany
    H. L. Bock & R. Clemens

Authors

  1. G. Hess
    You can also search for this author inPubMed Google Scholar
  2. V. Hingst
    You can also search for this author inPubMed Google Scholar
  3. J. Cseke
    You can also search for this author inPubMed Google Scholar
  4. H. L. Bock
    You can also search for this author inPubMed Google Scholar
  5. R. Clemens
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Hess, G., Hingst, V., Cseke, J. et al. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination.Eur. J. Clin. Microbiol. Infect. Dis. 11, 334–340 (1992). https://doi.org/10.1007/BF01962073

Download citation

Keywords